StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.37−0.39 (-5.03%)

Close on Nov 16, 2026Market cap $395.25MP/E –Yield –

Avalo Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Avalo Therapeutics's enterprise value was -$22.02M on Nov 11, 2026, against $227.13M a year earlier. Over the last 5 years it ranged from -$98.41M to $550.90M, with a median of $10.61M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$22.02M-110.4%
2025Dec 31, 2025$212.15M–
2024Dec 31, 2024-$9.92M–
2023Dec 29, 2023-$2.89M-106.1%
2022Dec 30, 2022$46.97M-60.6%
2021Dec 31, 2021$119.29M-27.3%
2020Dec 31, 2020$164.20M-33.7%
2019Dec 31, 2019$247.61M+77.0%
2018Dec 31, 2018$139.86M+135.6%
2017Dec 29, 2017$59.36M+2417.2%
2016Dec 30, 2016$2.36M-54.6%
2015Dec 31, 2015$5.20M–

More Avalo Therapeutics figures

See a number that looks wrong?